Literature DB >> 19834782

An alpha-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes.

Miwako Tsunosue, Naomi Mashiko, Yhukou Ohta, Yoshito Matsuo, Kouichi Ueda, Masayuki Ninomiya, Sho-ichi Tanaka, Masaru Hoshiko, Yasutsugu Yoshiyama, Masayoshi Takeuchi, Shin-ichiro Ueda, Sho-ichi Yamagishi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19834782     DOI： 10.1007/s10238-009-0074-9

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN： 1591-8890            Impact factor:   3.984


× No keyword cloud information.
  9 in total

1.  Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes.

Authors:  Y Jinnouchi; S Yamagishi; M Takeuchi; S Ishida; Y Jinnouchi; J Jinnouchi; T Imaizumi
Journal:  Clin Exp Med       Date:  2006-12       Impact factor: 3.984

2.  Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.

Authors:  M Hanefeld; S Fischer; U Julius; J Schulze; U Schwanebeck; H Schmechel; H J Ziegelasch; J Lindner
Journal:  Diabetologia       Date:  1996-12       Impact factor: 10.122

Review 3.  TAGE (toxic AGEs) theory in diabetic complications.

Authors:  Takashi Sato; Mina Iwaki; Noriko Shimogaito; Xuegang Wu; Sho-Ichi Yamagishi; Masayoshi Takeuchi
Journal:  Curr Mol Med       Date:  2006-05       Impact factor: 2.222

4.  Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe.

Authors: 
Journal:  Lancet       Date:  1999-08-21       Impact factor: 79.321

Review 5.  Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy.

Authors:  Sho-ichi Yamagishi; Tsutomu Imaizumi
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

Review 6.  Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders.

Authors:  Sho-ichi Yamagishi; Takanori Matsui; Seiji Ueda; Kei Fukami; Seiya Okuda
Journal:  Curr Drug Metab       Date:  2009-02       Impact factor: 3.731

7.  Glyceraldehyde-derived advanced glycation end products (AGEs). A novel biomarker of postprandial hyperglycaemia in diabetic rats.

Authors:  Y Kitahara; M Takeuchi; K Miura; T Mine; T Matsui; S Yamagishi
Journal:  Clin Exp Med       Date:  2008-09-13       Impact factor: 3.984

Review 8.  Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.

Authors:  Sho-Ichi Yamagishi; Kazuo Nakamura; Takanori Matsui; Seiji Ueda; Kei Fukami; Seiya Okuda
Journal:  Expert Opin Investig Drugs       Date:  2008-07       Impact factor: 6.206

9.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245
  9 in total
  10 in total

Review 1.  Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Akiko Sakasai-Sakai; Takanobu Takata; Tadashi Ueda; Mikihiro Tsutsumi; Hideyuki Hyogo; Sho-Ichi Yamagishi
Journal:  World J Hepatol       Date:  2014-12-27

2.  Impact of intracellular toxic advanced glycation end-products (TAGE) on murine myoblast cell death.

Authors:  Takanobu Takata; Akiko Sakasai-Sakai; Masayoshi Takeuchi
Journal:  Diabetol Metab Syndr       Date:  2020-06-29       Impact factor: 3.320

Review 3.  Toxic AGEs (TAGE) theory: a new concept for preventing the development of diseases related to lifestyle.

Authors:  Masayoshi Takeuchi
Journal:  Diabetol Metab Syndr       Date:  2020-11-30       Impact factor: 3.320

4.  Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.

Authors:  Sho-Ichi Yamagishi; Nobutaka Nakamura; Mika Suematsu; Kuniyoshi Kaseda; Takanori Matsui
Journal:  Mol Med       Date:  2015-10-27       Impact factor: 6.354

5.  Assessment of the concentrations of various advanced glycation end-products in beverages and foods that are commonly consumed in Japan.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Satomi Furuno; Hikari Shirai; Mihoko Kawakami; Michiru Muramatsu; Yuka Kobayashi; Sho-Ichi Yamagishi
Journal:  PLoS One       Date:  2015-03-02       Impact factor: 3.240

Review 6.  Effects of Toxic AGEs (TAGE) on Human Health.

Authors:  Masayoshi Takeuchi; Akiko Sakasai-Sakai; Takanobu Takata; Jun-Ichi Takino; Yoshiki Koriyama
Journal:  Cells       Date:  2022-07-12       Impact factor: 7.666

7.  Advanced glycation end products and their receptors in serum of patients with type 2 diabetes.

Authors:  Diana Indyk; Agnieszka Bronowicka-Szydełko; Andrzej Gamian; Aleksandra Kuzan
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

Review 8.  Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases.

Authors:  Masayoshi Takeuchi
Journal:  Diagnostics (Basel)       Date:  2016-06-07

Review 9.  Intracellular Toxic AGEs (TAGE) Triggers Numerous Types of Cell Damage.

Authors:  Masayoshi Takeuchi; Akiko Sakasai-Sakai; Takanobu Takata; Jun-Ichi Takino; Yoshiki Koriyama; Chigusa Kikuchi; Ayako Furukawa; Kentaro Nagamine; Takamitsu Hori; Tamihide Matsunaga
Journal:  Biomolecules       Date:  2021-03-05

10.  Intracellular Toxic Advanced Glycation End-Products in 1.4E7 Cell Line Induce Death with Reduction of Microtubule-Associated Protein 1 Light Chain 3 and p62.

Authors:  Takanobu Takata; Akiko Sakasai-Sakai; Masayoshi Takeuchi
Journal:  Nutrients       Date:  2022-01-13       Impact factor: 5.717
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.